2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-A0124A
    Sapropterin dihydrochloride 69056-38-8 ≥98.0%
    Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin also drives autoimmunity. Sapropterin can be used in study of phenylketonuria (PKU).
    Sapropterin dihydrochloride
  • HY-D0849
    Sodium iodoacetate 305-53-3
    Sodium iodoacetate is a specific inhibitor of GAPDH and has glycolysis inhibitory activity. In addition, sodium iodoacetate can induce osteoarthritis and related pain models in experimental animals.
    Sodium iodoacetate
  • HY-101455
    CDN1163 892711-75-0 99.90%
    CDN1163 is an allosteric sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activator that improves Ca2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders.
    CDN1163
  • HY-14268
    Febuxostat 144060-53-7 99.94%
    Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.
    Febuxostat
  • HY-B2130A
    Uric acid sodium 1198-77-2 ≥98.0%
    Uric acid sodium (Monosodium urate), scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid sodium can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation.
    Uric acid sodium
  • HY-17408
    Mevastatin 73573-88-3 99.46%
    Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.
    Mevastatin
  • HY-10284
    Linagliptin 668270-12-0 ≥98.0%
    Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
    Linagliptin
  • HY-12940
    GLPG0974 1391076-61-1 98.12%
    GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC50 of 9 nM.
    GLPG0974
  • HY-32351
    Calcifediol 19356-17-3 99.94%
    Calcifediol (25-hydroxy Vitamin D3) is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels.
    Calcifediol
  • HY-129993
    Gemfibrozil 1-O-β-glucuronide 91683-38-4 ≥98.0%
    Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil (CI-719; HY-B0258), is a potent and competitive P450 (CYP) isoform CYP2C8 inhibitor with an IC50 of 4.07 μM.
    Gemfibrozil 1-O-β-glucuronide
  • HY-135425
    10,12-Tricosadiynoic acid 66990-30-5 99.05%
    10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism. 10,12-Tricosadiynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    10,12-Tricosadiynoic acid
  • HY-W018392
    Mono-(2-ethylhexyl) phthalate 4376-20-9
    Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD).
    Mono-(2-ethylhexyl) phthalate
  • HY-113046
    5-Methyltetrahydrofolic acid 134-35-0 99.77%
    5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases.
    5-Methyltetrahydrofolic acid
  • HY-N0593A
    Deoxycholic acid sodium salt 302-95-4 ≥98.0%
    Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5.
    Deoxycholic acid sodium salt
  • HY-B1068
    Tyloxapol 25301-02-4
    Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol is used to induce hyperlipidemia in animals.
    Tyloxapol
  • HY-126304
    β-Glycerophosphate disodium salt hydrate 154804-51-0 ≥98.0%
    β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
    β-Glycerophosphate disodium salt hydrate
  • HY-16737
    Elafibranor 923978-27-2 99.66%
    Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis.
    Elafibranor
  • HY-14415
    SR8278 1254944-66-5 ≥98.0%
    SR8278 is a REV-ERBα antagonist and inhibits the REV-ERBα transcriptional repression activity with an EC50 of 0.47 μM. SR8278 is used to regulate the metabolism in organisms and study biological rhythm. SR8278 also can be used for the research of Duchenne muscular dystrophy and Alzheimer's disease.
    SR8278
  • HY-P9930
    Evolocumab 1256937-27-5
    Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation.
    Evolocumab
  • HY-17468
    Bumetanide 28395-03-1 99.95%
    Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
    Bumetanide
Cat. No. Product Name / Synonyms Application Reactivity